Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study results from Harvard University, Medical Department update understanding of breast cancer
May 28th, 2009
"The phosphoinositide 3-kinase (PI3K) pathway regulates a multitude of cellular processes. Deregulation of PI3K signaling Is often observed In human cancers," researchers in the United States report. "A major effector of PI3K is Akt/protein kinase B (PKB). Recent studies have pointed to distinct roles of Akt/PKB Isoforms in cancer cell signaling. Studies have shown that Akt1 (PKB alpha) can attenuate breast cancer cell motility, whereas Akt2 (PKB beta) enhances this phenotype. Here, we have evaluated the mechanism by which Akt1 blocks the migration of breast cancer cells through the transcription factor NFAT. A major effector of Akt/PKB Is glycogen synthase kInase-3...
Source: Women's Health Weekly (2009-05-28)
|
